EDGC Files Patent Application for New Anticancer Substance That Inhibits Cancer Cell Proliferation

EDGC, a precision medicine company specializing in genomic analysis, announced on the 13th that it has discovered a new anticancer substance capable of inhibiting the proliferation of cancer cells in major cancer types and has filed a patent for it.

EDGC's new drug development research team conducted efficacy screening using cell lines of colorectal cancer, breast cancer, and thyroid cancer, which have high incidence rates worldwide. They discovered a substance that inhibits the proliferation ability of cancer cells.

Last month, EDGC filed a patent for the substance and plans to sequentially conduct non-clinical and preclinical trials for the anticancer composition.

Earlier this year, EDGC reorganized its board of directors and focused its capabilities on new drug development by concretizing the new drug development pipeline. The company is emphasizing the activities of the new drug development research institute to create synergy between the genomic business and the new drug business. The new drug development research institute is discovering anticancer substances based on various biomarkers and is conducting non-clinical and preclinical trials independently.

At EDGC's new drug development research institute, research is also being conducted on refractory cancer types resistant to anticancer drugs. To develop treatments for refractory cancers, a research and development system using cancer cell lines resistant to standard anticancer drugs has been established. Animal experiments using this system are currently underway, and through continuous research and development, the anticancer drug development pipeline will be diversified.

Kim Yeon-jeong, head of EDGC's new drug development research institute, stated, "Through liquid biopsy-based genomic analysis, we are exploring the indications of various anticancer substances possessed by the new drug development research institute," adding, "Our goal is to develop anticancer new drugs that maximize anticancer efficacy and minimize toxicity."